Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.

Abstract

Aptamers are short DNA/RNA oligonucleotides selected by a process known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX) based on affinity for target molecules. Since aptamers have several advantages over monoclonal antibodies, such as high specificity and affinity, flexible modification and stability, and lack of toxicity and immunogenicity, they are promising novel diagnostic and therapeutic agents. In this review, we will describe the development of aptamers against thrombin, von Willebrand factor (vWF), factor IX, and factor XII as potential anticoagulants or antithrombotics for cardiovascular diseases, especially those that have entered clinical trials.

• Authors: Weibin Li, Kaiyu Wang, Meng Zhao, Xiangyue Yang, Min Chen, Xiaopeng Lan
• Journal: Thrombosis research (Thromb Res) Vol. 134 Issue 4 Pg. 769-73 (Oct 2014) ISSN: 1879-2472 [Electronic] United States
• PMID: 25113995 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2014. Published by Elsevier Ltd.

Chemical References

• Anticoagulants
• Aptamers, Nucleotide
• von Willebrand Factor
• Factor IX
• Factor XII
• Thrombin

Topics

• Animals
• Anticoagulants (therapeutic use)
• Aptamers, Nucleotide (therapeutic use)
• Cardiovascular Diseases (drug therapy, metabolism)
• Drug Discovery (methods)
• Factor IX (antagonists & inhibitors, metabolism)
• Factor XII (antagonists & inhibitors, metabolism)
• Humans
• Thrombin (antagonists & inhibitors, metabolism)
• von Willebrand Factor (antagonists & inhibitors, metabolism)